OGEN: oragenics.com Company Value to Net Income

Corporate emblem and logo of Oragenics Inc. (OGEN)

This daily price chart for Oragenics, Inc. (OGEN) reflects a value of -0.10. Production capacities for nasal products have been outsourced to third-party contractors in the US, eliminating equipment maintenance costs. The business relies on innovative drug delivery methods and promising developments. Oragenics, Inc. (OGEN) is currently shifting its strategic focus toward brain injury therapy and strict cost control.

Oragenics Inc. (OGEN) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Oragenics, Inc. (OGEN)

- price and consensus price forecast:
Stock Price Oragenics Inc.|OGEN - Consensus Target
- market capitalization information:
Market Value Oragenics, Inc.|OGEN - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Oragenics|OGEN - Company Book Value|Capitalization to Book Value Ratio oragenics.com|OGEN - Company Total Assets
- debt and solvency information:
Aggregate Debt to Equity Oragenics, Inc.|OGEN - Long-Term Debt to Capital|Current Liabilities to Capital oragenics.com|OGEN - Company Aggregate Debts|Debt to Book Value Oragenics, Inc.|OGEN - Company Long-Term Liabilities|Amount of Current Liabilities Oragenics|Interim Coverage Ratio oragenics.com
- earnings and market multiples details:
OGEN - Company Net Income|Expected Net Profit Oragenics, Inc.|OGEN - Price to Earnings Ratio|Price to Future Earnings Ratio Oragenics Inc.|OGEN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Oragenics, Inc.|OGEN - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Oragenics|OGEN - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months oragenics.com|OGEN - Earnings growth in current year|Earnings growth forecast for next year Oragenics, Inc.
- sales volume and revenue indicators:
OGEN - Revenue and Sales Volume|Company Sales Forecast oragenics.com|OGEN - P/S Multiple|Market Cap to Future Revenue Ratio Oragenics, Inc.
Summary company analysis:OGEN Oragenics Inc.
Manufactured products of Oragenics, Inc.

Institutional capital evaluates Oragenics, Inc. (OGEN) through the lens of profit generation efficiency per unit of market value. This payback ratio, reflected by the issuer's P/E ratio, determines the real value of holding positions during consolidation periods. It measures the investment return period based on current capitalization. The implementation of robotic bio-screening reduces costs, directly impacting net income and the dynamics of this multiple. Analyzing this metric allows for the differentiation of the asset's fundamental stability from temporary market fluctuations.

Competing companies

P/E Multiple summittxinc.com|Price to Earnings Ratio MRNA (Moderna)|PCVX (Vaxcyte Inc) - Company Value to Net Income|P/E Multiple TARS (Tarsus Pharma)|Business Payback Period CorMedix Therapeutics (CRMD)|MCRB - Price to Earnings Ratio|SPRO (sperotherapeutics.com) - Price to Earnings Multiple|SCYX: P/E Multiple|Market Cap to Net Income ANTX (AN2 Therapeutics)|PYPD (PolyPid Ltd) - P/E Multiple|Market Cap to Earnings YS Biopharma Co., Ltd. LSB|P/E Multiple ITRM|Price to Earnings Ratio biomx.com PHGE|Soligenix - Price to Earnings Ratio|Market Price to Net Income Ratio SXTP (60 Degrees Pharmaceuticals Inc.)|OpGen Corp - P/E Multiple